Microbot Medical launches limited U.S. commercial release of LIBERTY robotic system

Microbot Medical Inc.

LIBERTY Endovascular Robotic System now commercially available in U.S. on a limited basis after FDA 510(k) clearance in September 2025.
Limited Market Release (LMR) targets high procedure volume regions with existing preliminary demand; Full Market Release (FMR) planned for April 2026 at Society of Interventional Radiology meeting.
Company has hired core commercial team and secured third-party logistics partner to support the launch.
CEO Harel Gadot states the launch marks entry into commercialization phase, building a new robotic category with single-use system.

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-25-020815
form_type: 8-K
ticker: MBOT
cik: 0000883975
company_name: Microbot Medical Inc.
filed_at: 2025-11-05T23:59:59+00:00
discovered_at: 2026-05-14T18:02:42.470148+00:00
generated_at: 2026-05-17T00:29:22.235891+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-25-020815
json_url: https://secwatch.observer/filing/0001493152-25-020815.json
markdown_url: https://secwatch.observer/filing/0001493152-25-020815.md
text_url: https://secwatch.observer/filing/0001493152-25-020815.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/883975/000149315225020815/0001493152-25-020815-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/883975/000149315225020815/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-25-020815

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.